论文部分内容阅读
目的:研究奥拉西坦对咪达唑仑在大鼠体内药动学的影响。方法:采用高效液相色谱法,色谱条件:色谱柱为Dia-monsil C18柱(250 mm×4.6 mm,5μm),流动相为乙腈-水(62∶38),流速1.0mL·min-1,检测波长225 nm,柱温30℃,进样量20μL。实验组大鼠灌胃给予奥拉西坦5 d后,单次尾静脉注射咪达唑仑10 mg·kg-1,测定大鼠血浆中咪达唑仑浓度,计算药动学参数,并与对照组进行比较。结果:对照组与实验组主要药动学参数:t1/2分别为(0.9±0.6)h和(0.8±0.7)h,Cmax分别为(8.8±2.2)mg·L-1和(9.2±1.6)mg·L-1,AUC0-12 h分别为(3.1±0.5)mg.h.L-1和(3.7±0.6)mg·h.L-1,2组间差异无显著性。结论:奥拉西坦对咪达唑仑在大鼠体内主要药动学参数无明显影响。
Objective: To investigate the influence of oxiracetam on the pharmacokinetics of midazolam in rats. Methods: The HPLC conditions were as follows: Dia-monsil C18 column (250 mm × 4.6 mm, 5 μm) with the mobile phase of acetonitrile-water (62:38), flow rate of 1.0 mL · min-1, Detection wavelength of 225 nm, column temperature 30 ℃, the injection volume of 20μL. Rats in the experimental group were given oxalatetin orally for 5 days. Midazolam 10 mg · kg-1 was injected into the caudal vein to measure the concentration of midazolam in the rat plasma, and the pharmacokinetic parameters were calculated. Control group for comparison. RESULTS: The main pharmacokinetic parameters of control group and experimental group were (0.9 ± 0.6) h and (0.8 ± 0.7) h, respectively, and the C max were (8.8 ± 2.2) mg · L -1 and (9.2 ± 1.6) ) mg · L-1, AUC0-12 h were (3.1 ± 0.5) mg.hL-1 and (3.7 ± 0.6) mg · h-1, respectively. There was no significant difference between the two groups. Conclusion: Oxiracetam has no significant effect on the main pharmacokinetic parameters of midazolam in rats.